| ABVX Stock | | | EUR 7.75 0.30 3.73% |
President
Dr. Alexandra Pearce was appointed as Vice President and Head of Regulatory Affairs of the Company., effective May 21, 2018 since 2018.
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 33 1 53 83 08 41 |
| Web | https://www.abivax.com |
Pearce joins ABIVAX from Viramal, where she served as Chief Operations Officer and Head of Regulatory Affairs. Previously, she held roles as Executive Vice President and Head of Global Regulatory Affairs for Glenmark, responsible for regulatory strategy, drug development and the successful commercialization of all inhouse and inlicensed products spanning 80 countries. Prior to this, as Executive Director, Global Regulatory Affairs and Safety at Amgen, she was responsible for developing and executing global regulatory strategies for early pipeline molecules across all therapeutic areas. Before joining Amgen, Dr. Pearce was the Global Regulatory Leader and Director of Worldwide Regulatory Strategy at Pfizer. In this role, Dr. Pearce was accountable for current and emerging business interests for products within the cardiovascular portfolio, as well as serving as Pfizer regulatory liaison with the FDA
Abivax SA Management Efficiency
The company has return on total asset
(ROA) of
(0.4368) % which means that it has lost $0.4368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(12.8647) %, meaning that it generated substantial loss on money invested by shareholders. Abivax SA's management efficiency ratios could be used to measure how well Abivax SA manages its routine affairs as well as how well it operates its assets and liabilities.
Abivax SA has accumulated 53.45
M in total debt with debt to equity ratio
(D/E) of 31.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abivax SA has a current ratio of 2.16, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Abivax SA until it has trouble settling it off, either with new capital or with free cash flow. So, Abivax SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abivax SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abivax to invest in growth at high rates of return. When we think about Abivax SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
ABIVAX Socit Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. The company was incorporated in 2013 and is headquartered in Paris, France. ABIVAX is traded on Paris Stock Exchange in France. Abivax SA (ABVX) is traded on Euronext Paris in France and employs 24 people.
Management Performance
Abivax SA Leadership Team
Elected by the shareholders, the Abivax SA's board of directors comprises two types of representatives: Abivax SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abivax. The board's role is to monitor Abivax SA's management team and ensure that shareholders' interests are well served. Abivax SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abivax SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Didier Blondel, CFO, Board Secretary | |
| Alain Chevallier, Advisor | |
| Philippe MD, Founder Director | |
| Regina Jehle, VP Communications | |
| Prof Ehrlich, Chief Officer | |
| Paul Gineste, VP Operations | |
| Anne Pascard, HR Mang | |
| Raquel Lizarraga, Investor Mang | |
| Pierre MBA, Chief Devel | |
| Alexandra Pearce, Vice President and Head of Regulatory Affairs | |
Abivax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abivax SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Abivax Stock
Abivax SA financial ratios help investors to determine whether Abivax Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abivax with respect to the benefits of owning Abivax SA security.